Formulations and dosage forms of oxidized phospholipids

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9254297
APP PUB NO 20130209555A1
SERIAL NO

13792633

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The current disclosure provides pharmaceutical compositions containing an oxidized phospholipid, such as 1-hexadecyl-2-(4′-carboxybutyl)-glycero-3-phosphocholine (VB-201) and a thermosoftening carrier, e.g., a poloxamer. The pharmaceutical compositions may further comprise an anti-adherent agent, such as talc and/or a thixotropic agent. The current disclosure further provides processes for preparing the pharmaceutical compositions. The disclosure further provides capsules containing the pharmaceutical compositions. Uses of such pharmaceutical compositions and capsules in treating inflammatory disorders are also disclosed.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
VASCULAR BIOGENICS LTDMODIIN 7178106

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bakhshaee, Massoud Glasgow, GB 8 80
McNaughton, Alyn West Lothian, GB 3 21
Sher, Naamit Rohovot, IL 13 100
Wilding, Ian Robert Beeston, GB 4 40
Young, Victor M Midlothian, GB 3 21

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 9, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00